Utilization and expense of adjuvant cancer therapies following radical prostatectomy

Medicine and Dentistry

• Adjuvant Therapy 100%
• Prostatectomy 100%
• Cancer Adjuvant Therapy 100%
• Hazard Ratio 60%
• Disease 20%
• Health Care 20%
• Radiation Therapy 20%
• Surgeon 20%
• Hormone Therapy 20%
• High Risk Population 20%
• Malignant Neoplasm 10%
• Medicare 10%
• Health Care Cost 10%
• Lymph Node 10%
• Surgical Approach 10%
• Surgical Margin 10%
• Biopsy Technique 10%
• Low Risk Population 10%
• Proportional Hazards Model 10%
• Prostate Specific Antigen 10%
• Gleason Score 10%
• Comorbidity 10%

Keyphrases

• Adjuvant Therapy 100%
• Radical Prostatectomy 100%
• Confidence Interval 54%
• Hazard Ratio 54%
• Hormonal Therapy 18%
• Healthcare Expenditure 18%
• Medicare Data 9%
• SEER-Medicare 9%
• Comorbidity 9%
• Iowa 9%
• Radiotherapy 9%
• Prostate-specific Antigen 9%
• Disease Pattern 9%
• New Mexico 9%
• High-risk Population 9%
• High-risk Disease 9%
• Surgical Approach 9%
• Georgia 9%
• Non-associated 9%
• Radiation Therapy 9%
• San Francisco 9%
• Lymph Node Positive 9%
• Regional Variation 9%
• Cox Regression 9%
• Positive Surgical Margin 9%
• Low-risk Group 9%
• Node-positive Disease 9%
• Hawaii 9%
• High-volume Surgeon 9%
• Surgeon Volume 9%
• Biopsy Gleason Score 9%
• Post-prostatectomy 9%